Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dapi. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.79 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.79 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.79 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.79 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.79 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.79 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.79 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.79 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.79 |
| ▸ | F2 | P00734 | 2/20 | 0.60 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapi SCHEMBL15966967 | 1.00 | PRMT5 (0.79) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL2464378 | 0.98 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL30442885 | 0.98 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL94350 | 0.98 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL29350295 | 0.97 | PRMT5 (0.83) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL28176609 | 0.97 | PRMT5 (0.83) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL235865 | 0.97 | PRMT5 (0.83) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| SCHEMBL29428907 | 0.95 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| SCHEMBL14854556 | 0.95 | PRMT5 (0.81) | PRMT5PRMT3CARM1EHMT2PRMT6 | |
| Dapi SCHEMBL1609032 | 0.94 | PRMT5 (0.79) | PRMT5PRMT3CARM1EHMT2PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210222226-A1 | METHODS OF MEASURING ENZYME ACTIVITY IN COATING COMPOSTIONS | BASF SE (DE) | 2021-07-22 | — | — | US | claimed |
| EP-3814518-A1 | METHODS OF MEASURING ENZYME ACTIVITY IN COATING COMPOSITIONS | BASF SE (DE) | 2021-05-05 | — | — | EP | claimed |
| CN-112513287-A | Method for measuring enzyme activity in coating compositions | 巴斯夫欧洲公司 | 2021-03-16 | — | — | CN | claimed |
| US-5403744-A | Colorimetric analysis using metachromatic dye, pH indicator dye, polyelectrolytes with anionic sites to bind with dyes; for testing urine, blood | MILES INC. (US) | 1995-04-04 | — | — | US | claimed |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20210222226-A1 | METHODS OF MEASURING ENZYME ACTIVITY IN COATING COMPOSTIONS | BASF SE (DE) | 2021-07-22 | — | — | US | disclosed |
| EP-3814518-A1 | METHODS OF MEASURING ENZYME ACTIVITY IN COATING COMPOSITIONS | BASF SE (DE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112513287-A | Method for measuring enzyme activity in coating compositions | 巴斯夫欧洲公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020191227-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-3034093-B1 | COMPOSITIONS AND METHODS OF TREATING TUMORS | UNIV PENNSYLVANIA (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9901608-B2 | Composition and method for enhancing alcohol metabolism | Gangneung-Wonju National University Industry Academy Cooperation Group (KR) | 2018-02-27 | — | — | US | disclosed |
| EP-2363410-B1 | Isoforms of MUC1 | MINERVA BIOTECHNOLOGIES CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-1999021574-A9 | ENHANCEMENT OF MORPHOGEN ACTIVITY | CREATIVE BIOMOLECULES INC (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999021574-A2 | ENHANCEMENT OF MORPHOGEN ACTIVITY | CREATIVE BIOMOLECULES, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| EP-0558740-B1 | PROBE COMPOSITION FOR GENOME IDENTIFICATION AND METHODS | VYSIS INC (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5789161-A | Methods for genome identification using direct label probe composition | AMOCO CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| US-5403744-A | Colorimetric analysis using metachromatic dye, pH indicator dye, polyelectrolytes with anionic sites to bind with dyes; for testing urine, blood | MILES INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0611966-A1 | Method, composition and device for measuring the ionic strength or specific gravity of a test sample | Bayer Corporation (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0558740-A1 | PROBE COMPOSITION FOR GENOME IDENTIFICATION AND METHODS | VYSIS, Inc. (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1993006245-A1 | PROBE COMPOSITION FOR GENOME IDENTIFICATION AND METHODS | AMOCO CORPORATION (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | PRMT5 3685/4885PRMT3 3403/4885CARM1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.